CN105285288A - 一种辅助治疗咽喉炎的奶糖及其制备方法 - Google Patents
一种辅助治疗咽喉炎的奶糖及其制备方法 Download PDFInfo
- Publication number
- CN105285288A CN105285288A CN201510672818.2A CN201510672818A CN105285288A CN 105285288 A CN105285288 A CN 105285288A CN 201510672818 A CN201510672818 A CN 201510672818A CN 105285288 A CN105285288 A CN 105285288A
- Authority
- CN
- China
- Prior art keywords
- parts
- tendril
- candy
- mushroom
- orange peel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000009508 confectionery Nutrition 0.000 title abstract description 16
- 238000002360 preparation method Methods 0.000 title abstract description 11
- 241000935235 Fritillaria meleagris Species 0.000 claims abstract description 21
- 229940087603 grape seed extract Drugs 0.000 claims abstract description 15
- 235000002532 grape seed extract Nutrition 0.000 claims abstract description 15
- 239000001717 vitis vinifera seed extract Substances 0.000 claims abstract description 15
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 12
- 239000008103 glucose Substances 0.000 claims abstract description 12
- 239000006188 syrup Substances 0.000 claims abstract description 12
- 235000020357 syrup Nutrition 0.000 claims abstract description 12
- 239000002994 raw material Substances 0.000 claims abstract description 9
- 244000179886 Moringa oleifera Species 0.000 claims abstract description 3
- 235000011347 Moringa oleifera Nutrition 0.000 claims abstract description 3
- 239000000843 powder Substances 0.000 claims abstract description 3
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims description 23
- 241000405414 Rehmannia Species 0.000 claims description 18
- 244000246386 Mentha pulegium Species 0.000 claims description 14
- 235000016257 Mentha pulegium Nutrition 0.000 claims description 14
- 235000004357 Mentha x piperita Nutrition 0.000 claims description 14
- 235000001050 hortel pimenta Nutrition 0.000 claims description 14
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 11
- 229930006000 Sucrose Natural products 0.000 claims description 11
- 230000000153 supplemental effect Effects 0.000 claims description 10
- 235000015149 toffees Nutrition 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 239000000284 extract Substances 0.000 claims description 8
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 8
- 235000006886 Zingiber officinale Nutrition 0.000 claims description 5
- 235000008397 ginger Nutrition 0.000 claims description 5
- 238000009835 boiling Methods 0.000 claims description 4
- 238000005266 casting Methods 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 239000012467 final product Substances 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 244000273928 Zingiber officinale Species 0.000 claims 1
- 235000013305 food Nutrition 0.000 abstract description 2
- 240000000599 Lentinula edodes Species 0.000 abstract 1
- 235000006679 Mentha X verticillata Nutrition 0.000 abstract 1
- 235000002899 Mentha suaveolens Nutrition 0.000 abstract 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 35
- 206010062717 Increased upper airway secretion Diseases 0.000 description 18
- 208000026435 phlegm Diseases 0.000 description 18
- 230000006870 function Effects 0.000 description 13
- 230000003110 anti-inflammatory effect Effects 0.000 description 10
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 9
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- 210000004072 lung Anatomy 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 150000003254 radicals Chemical class 0.000 description 6
- 241000234314 Zingiber Species 0.000 description 5
- 230000000954 anitussive effect Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 5
- 229930182490 saponin Natural products 0.000 description 5
- 150000007949 saponins Chemical class 0.000 description 5
- 206010011224 Cough Diseases 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 241000191967 Staphylococcus aureus Species 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000000341 volatile oil Substances 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 3
- 241000700199 Cavia porcellus Species 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000003266 anti-allergic effect Effects 0.000 description 3
- 210000000748 cardiovascular system Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000004089 microcirculation Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- -1 Chromocor compound Chemical class 0.000 description 2
- 206010008909 Chronic Hepatitis Diseases 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 206010018691 Granuloma Diseases 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 229920000715 Mucilage Polymers 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- URLKBWYHVLBVBO-UHFFFAOYSA-N Para-Xylene Chemical group CC1=CC=C(C)C=C1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 description 2
- 206010034568 Peripheral coldness Diseases 0.000 description 2
- 208000005374 Poisoning Diseases 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 241000191963 Staphylococcus epidermidis Species 0.000 description 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- 208000037386 Typhoid Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- BAKQMOSGYGQJOJ-RMPHRYRLSA-N [(1r,2r,3s,4r,5r)-3,4-diacetyloxy-6,8-dioxabicyclo[3.2.1]octan-2-yl] acetate Chemical compound O1[C@@]2([H])OC[C@]1([H])[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]2OC(C)=O BAKQMOSGYGQJOJ-RMPHRYRLSA-N 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- 230000001088 anti-asthma Effects 0.000 description 2
- 230000001387 anti-histamine Effects 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000004856 capillary permeability Effects 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 235000014103 egg white Nutrition 0.000 description 2
- 210000000969 egg white Anatomy 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 231100000753 hepatic injury Toxicity 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 2
- 238000003305 oral gavage Methods 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000000242 pagocytic effect Effects 0.000 description 2
- 231100000572 poisoning Toxicity 0.000 description 2
- 230000000607 poisoning effect Effects 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000005057 refrigeration Methods 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- YRCWQPVGYLYSOX-UHFFFAOYSA-N synephrine Chemical compound CNCC(O)C1=CC=C(O)C=C1 YRCWQPVGYLYSOX-UHFFFAOYSA-N 0.000 description 2
- 201000008297 typhoid fever Diseases 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
- XMGQYMWWDOXHJM-JTQLQIEISA-N (+)-α-limonene Chemical group CC(=C)[C@@H]1CCC(C)=CC1 XMGQYMWWDOXHJM-JTQLQIEISA-N 0.000 description 1
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 1
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- FTVWIRXFELQLPI-ZDUSSCGKSA-N (S)-naringenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-ZDUSSCGKSA-N 0.000 description 1
- 125000001340 2-chloroethyl group Chemical class [H]C([H])(Cl)C([H])([H])* 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 208000009079 Bronchial Spasm Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 102100034279 Calcium-binding mitochondrial carrier protein Aralar2 Human genes 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- WTEVQBCEXWBHNA-UHFFFAOYSA-N Citral Natural products CC(C)=CCCC(C)=CC=O WTEVQBCEXWBHNA-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 244000168525 Croton tiglium Species 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
- 244000061508 Eriobotrya japonica Species 0.000 description 1
- 235000009008 Eriobotrya japonica Nutrition 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 240000000231 Ficus thonningii Species 0.000 description 1
- 208000001034 Frostbite Diseases 0.000 description 1
- 241000175212 Herpesvirales Species 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 241000192041 Micrococcus Species 0.000 description 1
- 241000237852 Mollusca Species 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 241001522129 Pinellia Species 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 241000607762 Shigella flexneri Species 0.000 description 1
- 241000607760 Shigella sonnei Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000194019 Streptococcus mutans Species 0.000 description 1
- 244000185386 Thladiantha grosvenorii Species 0.000 description 1
- 235000011171 Thladiantha grosvenorii Nutrition 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 241000219095 Vitis Species 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- PECIYKGSSMCNHN-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=NC=N[C]21.O=C1N(C)C(=O)N(C)C2=NC=N[C]21 PECIYKGSSMCNHN-UHFFFAOYSA-N 0.000 description 1
- 229960003556 aminophylline Drugs 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 229940085430 aspirin 300 mg Drugs 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000003181 biological factor Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000004044 bronchoconstricting agent Substances 0.000 description 1
- 230000002741 bronchospastic effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000001013 cariogenic effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 229940043350 citral Drugs 0.000 description 1
- 108010084210 citrin Proteins 0.000 description 1
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- WWULHQLTPGKDAM-UHFFFAOYSA-N gamma-eudesmol Natural products CC(C)C1CC(O)C2(C)CCCC(=C2C1)C WWULHQLTPGKDAM-UHFFFAOYSA-N 0.000 description 1
- WTEVQBCEXWBHNA-JXMROGBWSA-N geranial Chemical compound CC(C)=CCC\C(C)=C\C=O WTEVQBCEXWBHNA-JXMROGBWSA-N 0.000 description 1
- NLDDIKRKFXEWBK-AWEZNQCLSA-N gingerol Chemical compound CCCCC[C@H](O)CC(=O)CCC1=CC=C(O)C(OC)=C1 NLDDIKRKFXEWBK-AWEZNQCLSA-N 0.000 description 1
- JZLXEKNVCWMYHI-UHFFFAOYSA-N gingerol Natural products CCCCC(O)CC(=O)CCC1=CC=C(O)C(OC)=C1 JZLXEKNVCWMYHI-UHFFFAOYSA-N 0.000 description 1
- 235000002780 gingerol Nutrition 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 208000010758 granulomatous inflammation Diseases 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 229940025878 hesperidin Drugs 0.000 description 1
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 229940117954 naringenin Drugs 0.000 description 1
- WGEYAGZBLYNDFV-UHFFFAOYSA-N naringenin Natural products C1(=O)C2=C(O)C=C(O)C=C2OC(C1)C1=CC=C(CC1)O WGEYAGZBLYNDFV-UHFFFAOYSA-N 0.000 description 1
- 235000007625 naringenin Nutrition 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- ARGKVCXINMKCAZ-UZRWAPQLSA-N neohesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@H]3[C@@H]([C@H](O)[C@@H](O)[C@H](C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UZRWAPQLSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 229960003684 oxedrine Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000002310 reflectometry Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- CEIZFXOZIQNICU-UHFFFAOYSA-N tenuazonic acid Chemical compound CCC(C)C1NC(=O)C(C(C)=O)=C1O CEIZFXOZIQNICU-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明属于保健糖果技术领域,具体涉及一种辅助治疗咽喉炎的奶糖及其制备方法,其由下述重量配比的原料制成:薄荷6-7份、川贝2-3份,生地3-4份、陈皮0.5-1份、香菇3-4份,葡萄籽提取物2-3份,辣木籽粉110-119份,葡萄糖浆200-280份。本发明所用原料全部可以在市场上获得,都是药食同源的食品,来源广泛、味道独特、质量稳定、辅助治疗咽喉炎有一定功效。
Description
技术领域
本发明属于保健糖果技术领域,具体涉及一种辅助治疗咽喉炎的奶糖及其制备方法。
背景技术
传统糖果多是为人类提供一种悠闲零食,能不能在吃零食的同时,又可以具有其他作用呢。目前市场上提供了许多添加了罗汉果、枇杷、菊花等提取物的糖果,使其具有润喉、止咳、祛痰等功效,然而,效果不是很好,多是处于一种卖概念、卖噱头,进行心理安慰的阶段。另外,市场上也出现了一些以美容美肤为特点的糖果。但是,既有止咳作用,又有美容作用的糖果还没有发现。
发明内容
本发明的目的是提供一种辅助治疗咽喉炎的奶糖及其制备方法,具有味道独特、防治咽喉炎、美容美肤等优点。
本发明所采用的技术方案如下:
一种辅助治疗咽喉炎的奶糖及其制备方法,其特征在于由下述重量配比的原料制成:
薄荷6-7份、川贝2-3份,生地3-4份、陈皮0.5-1份、香菇3-4份,葡萄籽提取物2-3份,辣木籽粉110-119份,葡萄糖浆200-280份。
本发明更优选的技术方案可以是:
一种辅助治疗咽喉炎的奶糖及其制备方法,其特征在于由下述重量配比的原料制成:
薄荷6.5份、川贝2.4份,生地3.5份、陈皮0.8份、香菇3.6份,葡萄籽提取物2.5份,白糖260份,葡萄糖浆220份。
制备方法:
1、将薄荷、川贝、生地、香菇加水煎煮提取清膏,过滤,浓缩至相对密度60℃约1.30;
2、将陈皮榨汁,过滤;
3、将1、2步骤所得的浸膏和姜汁,还有葡萄籽提取物混合均匀,备用,
4、将白糖粉碎至80目;
5、将白糖粉置于锅内,加适量水,进行熬制,待白糖溶化后加入葡萄糖浆搅拌均匀,再加入步骤3中的混合备用物,搅拌均匀。
6、出锅注模成型。
7、出模包装即得。
本发明的功效及药理研究分析:
薄荷:临床常用于咽喉炎痰多、胸闷腹胀的痰湿证或外感风寒、咽喉炎有痰者。现代研究,薄荷的主要成分:含挥发油1.9%~3.5%;此外,尚含橙皮甙、新橙皮甙、柑橘素;黄酮化合物、枸橼醛、β-谷甾醇、对羟福林等。药理作用:(1)祛痰、平喘作用:所含挥发油有刺激性祛痰作用,主要成分为柠檬烯。完全对抗组胺所引起的豚鼠离体支气管痉挛性收缩。对支气管哮喘有一定疗效。动物实验表明:注射给药,有支气管扩张作用,强度略逊于氨茶碱;但静注、肌注、灌肠、灌胃,则均不能对抗组胺引起的支气管痉挛。甲基橙皮甙对豚鼠离体气管的解痉作用甚小。(2)对心血管系统的作用:橙皮甙静脉注射,能使在位兔心收缩力增强,心输出量增加,但对心率无明显影响。含有氧化产物的橙皮甙能提高兔心收缩力及心率,而纯品则无效。甲基橙皮甙40mg/kg给犬静脉滴注,有降低冠脉阻力、增加冠脉流量、降低血压、减慢心率作用;但对心肌耗氧量、心肌氧利用率、心肌收缩力则无明显影响。橙皮甙对猫的周围血管有短时而明显的扩张作用,但不含氧化物的纯品则无效。磷酰橙皮甙对实验性高血脂兔,有降低血清胆固醇的作用,并能明显地减轻和改善其主动脉粥样硬化病变。(3)抗病原微生物作用 在试管内可抑制葡萄球菌的生长,与小叶榕合剂在体外对绿脓杆菌、金黄色葡萄球菌、福氏痢疾杆菌、变形杆菌亦有抗菌作用。陈皮甙能预防流感病毒的感染,但其抗病毒活性能被透明质酸酶所消除。(4)抗炎、抗过敏作用 橙皮甙有维生素P样作用,能降低毛细血管通透性,防止微血管出血;可以拮抗组胺、溶血卵磷脂引起的血管通透性增加。橙皮甙皮下注射能减轻大鼠肉芽肿炎症反应。橙皮甙每日20~25mg/kg给兔口服,无论是预服7天或是在实验前后各服7天,对氯乙烷造成的耳部冻伤均有减轻症状的效果。
川贝:为川贝科植物川贝的根。味苦、辛,性平。入肺、胃经。功能:开宣肺气、祛痰、利咽、排脓。主治:外感咽喉炎、咽喉肿痛、肺痈吐脓、胸满胁痛、痢疾腹痛。现代研究其药理作用有:(1)祛痰作用 川贝煎剂给麻醉犬口服1g/kg后,能使呼吸道黏液分泌量显著增加,作用强度与氯化铵相似。对麻醉猫亦有促进呼吸道黏液分泌的作用。其机制是由于川贝中所含皂甙,能刺激胃黏膜,引起轻度恶心,反射性引起支气管腺体分泌增多,稀释痰液,而发挥祛痰作用。(2).镇咳作用 用豚鼠气管刺激法,川贝皂甙15mg/kg有镇咳作用。粗制川贝皂甙给麻醉豚鼠腹腔注射,其半数镇咳有效量为6.4mg/kg,提示其有较强的镇咳作用。(3)抗炎作用 川贝皂甙对急性及慢性炎症有较强的抗炎作用。川贝皂甙,对大鼠角叉菜胶性足肿胀、醋酸性足肿胀有抑制作用;对大鼠棉球肉芽肿的形成也有显著抑制作用;对大鼠佐剂性关节炎亦有效。
生地:生地提取液对金黄色葡萄球菌有效,而对大肠杆菌则否。对慢性气管炎中某些常见细菌(肺炎球菌、甲型链球菌、卡他球菌)也有抑菌作用(平板法)。生地对致龋菌──变形链球菌,有较好的抑菌和杀菌作用。生地水煎剂(1:20)在人胚肾代原单层上皮细胞组织培养上,对流感病毒、孤儿病毒、疱疹病毒均有抑制作用。(2)降血脂作用 给禁食大鼠服大量胆固醇,如同时服生地(2.5g/kg),则能减少肠道对胆固醇的吸收,降低血浆中胆固醇的含量。(3)抗炎及解热作用:生地提取液腹腔注射能抑制大鼠角叉菜胶性脚肿,减轻蛋清性脚肿程度。对大鼠巴豆油性肉芽囊,亦有明显的抗渗出和抗增生作用。(4)对免疫功能的作用:生地煎剂能促进白细胞的吞噬功能。对细胞免疫有抑制作用。小鼠腹腔注射生地注射液,也有明显促进炎性细胞吞噬功能的作用。
陈皮:为姜科植物姜的鲜根茎。味辛,性温。入肺、胃、脾经。功能:发表、散寒、止呕、开痰。主治:感冒风寒、呕吐、痰饮、喘满、胀满、泄泻;解半夏、天南星及鱼蟹、鸟兽肉毒。其主要成分:陈皮含挥发油0.25%~3.0%。实验证明陈皮油0.4ml/kg给大鼠灌胃,对蛋清性足肿有显著抑制作用,作用维持5小时,强度近似阿司匹林300mg/kg;0.25ml/kg给大鼠灌胃,可显著抑制棉球肉芽肿,并使胸腺萎缩,肾上腺重量增加,提示其抗炎作用可能与兴奋垂体-肾上腺皮质系统有关。陈皮油0.25~0.4ml/kg灌胃,对二甲苯所致小鼠耳郭肿胀、组胺或醋酸所致毛细血管通透性增强有显著抑制作用。小鼠腹腔注射鲜姜注射液5g/kg或10g/kg,有明显的镇痛作用。(2)另外陈皮还有抗病原微生物作用:陈皮提取液对金黄色葡萄球菌、白色葡萄球菌、伤寒杆菌、宋内痢疾杆菌、绿脓杆菌均有明显抑制作用,尤以金黄色葡萄球菌和白色葡萄球菌的抑制作用最强。陈皮水浸剂在体外对伤寒杆菌及霍乱弧菌有强烈的杀菌作用。在试管内对毛癣菌有抑制作用。姜根茎中的姜醇和姜酚具有杀灭软体动物和杀灭血吸虫的作用。
香菇:主要成分:含氨基酸、多肽、蛋白质、真菌溶菌酶(fungallysozyme),以及糖类(还原糖和多糖)、麦角甾醇、三萜类、香豆精甙、挥发油、硬脂酸、苯甲酸、生物碱、维生素B2及C等;孢子还含甘露醇、海藻糖(trehalose)。
功能主治:(1)心神不宁,失眠,惊悸。该品味甘性平,入心经,能补心血、益心气、安心神,故可用治气血不足、心神失养所致的心神不宁、失眠、惊悸、多梦、健忘、体倦神疲、食少等症。(2)咳喘痰多。该品味甘能补,性平偏温,入肺经,补益肺气,温肺化痰,止咳平喘,常可治痰饮证,见形寒咽喉炎、痰多气喘者,尤其对痰湿型或虚寒型疗效较好。(3)虚劳症。该品有补养气血作用,故常用治虚劳短气、不思饮食、手足逆冷、或烦躁口干等症。(4)保肝解毒:香菇对多种理化及生物因素引起的肝损伤有保护作用。无论在肝脏损害发生前还是发生后,服用香菇都可保护肝脏,减轻肝损伤。香菇能促进肝脏对药物、毒物的代谢,对于中毒性肝炎有确切的疗效。尤其是慢性肝炎,香菇可明显消除头晕、乏力、恶心、肝区不适等症状,并可有效地改善肝功能,使各项指标趋于正常。所以,香菇可用于治疗慢性中毒、各类慢性肝炎、肝硬化、肝功能障碍。(5)改善心血管系统:动物实验和临床试验均表明,香菇可有效地扩张冠状动脉,增加冠脉血流量,改善心肌微循环,增强心肌氧和能量的供给,因此,对心肌缺血具有保护作用,可广泛用于冠心病、心绞痛等的治疗和预防。对高血脂病患者,香菇可明显降低血胆固醇、脂蛋白和甘油三脂,并能预防动脉粥样硬化斑块的形成。对于粥样硬化斑块已经形成者,则有降低动脉壁胆固醇含量、软化血管、防止进一步损伤的作用。并可改善局部微循环,阻止血小板聚集。(6)肌肤美白:李时珍在《本草纲目》中就指出香菇有“增智慧,好颜色”,香菇是一种具有抗皱、消炎、清除色斑、保护皮肤。香菇含有抑制黑色素的成分及多种对皮肤有益的微量元素等,这些成分能够通过减少人体自由基,加速细胞的再生,增加皮肤的厚度并增加胶原质,达到丰润皮肤、消除细纹与皱纹的效果。其中的多糖成分能够通过保持和调节皮肤水性,恢复皮肤弹性,使皮肤湿润、细腻。
葡萄籽提取物:是从葡萄籽中提取的一种人体内不能合成的新型高效天然抗氧化剂物质。它是目前自然界中发现的抗氧化、清除自由基能力最强的物质,其抗氧化活性为维素E的50倍、维生素C的20倍,它能有效清除人体内多余的自由基,具有超强的延缓衰老和增强免疫力的作用。抗氧化、抗过敏、抗疲劳增强体质、改善亚健康状态延缓衰老、改善烦躁易怒、头昏乏力、记忆力减退等症状。
综上所述,本发明所述辅助治疗咽喉炎的奶糖,薄荷有祛痰、平喘作用、抗病原微生物作用、对心血管系统的作用、抗炎、抗过敏作用;川贝有祛痰作用、镇咳作用、抗炎作用;生地有抗病原微生物作用、降血脂作用、增强免疫功能的作用、抗炎及解热作用;陈皮有抗炎、抗病原微生物作用;香菇、葡萄籽提取物具有强大的解毒作用,能消除体内毒素、自由基从而保健美容。香菇具有改善微循环作用,又可以增强药物和免疫细胞的转运,从而辅助引细菌感染炎症反应引起的咽喉炎。病菌入侵人体,人体解毒功能下降,就会产生许多毒素和自由基,毒素和自由基的积累,就会使人皮肤变差,所以本发明利用葡萄籽提取物,比维生素e、维生素c的作用强大,而清除毒素和自由基等也是治疗细菌引起的咽喉炎所需要的。所以,本发明止咳类药和美容类药互相有协同作用,从而使得本发明的目的得以很好实现。另外,虽然葡萄籽提取物味道较涩,但是经过陈皮、薄荷、白糖、葡萄糖浆的调味,味道可口而有姜橙甜味。本发明所用原料全部可以在市场上获得,都是药食同源的食品,来源广泛、质量稳定、辅助治疗咽喉炎有一定功效。
具体实施方式
实施例1
称取以下述重量配比的原料:
薄荷6kg、川贝2kg,生地3kg、陈皮0.5kg、香菇3kg,葡萄籽提取物2kg,白糖200kg,葡萄糖浆200kg。
本发明的制备方法:
1、将薄荷、川贝、生地、香菇加水煎煮提取清膏,过滤,浓缩至相对密度约1.30(60℃);
2、将陈皮榨汁,过滤;
3、将1、2步骤所得的浸膏和姜汁,还有葡萄籽提取物混合均匀,备用,
4、将白糖粉碎至80目;
5、将白糖粉置于锅内,加适量水(水量约为白糖的10-20%),进行熬制,待白糖溶化后加入葡萄糖浆搅拌均匀,再加入步骤3中的混合备用物,搅拌均匀。
6、出锅注模成型。
7、出模包装即得。
实施例2
称取以下述重量配比的原料:
薄荷7kg、川贝3kg,生地4kg、陈皮1kg、香菇4kg,葡萄籽提取物3kg,白糖300kg,葡萄糖浆280kg。
本发明的制备方法:
1、将薄荷、川贝、生地、香菇加水煎煮提取清膏,过滤,浓缩至相对密度约1.30(60℃);
2、将陈皮榨汁,过滤;
3、将1、2步骤所得的浸膏和姜汁,还有葡萄籽提取物混合均匀,备用,
4、将白糖粉碎至80目;
5、将白糖粉置于锅内,加适量水(水量约为白糖的10-20%),进行熬制,待白糖溶化后加入葡萄糖浆搅拌均匀,再加入步骤3中的混合备用物,搅拌均匀。
6、出锅注模成型。
7、出模包装即得。
Claims (3)
1.一种辅助辅助治疗咽喉炎的奶糖,其特征在于由下述重量配比的原料制成:
薄荷6-7份、川贝2-3份,生地3-4份、陈皮0.5-1份、香菇3-4份,葡萄籽提取物2-3份,辣木籽粉110-119份,葡萄糖浆200-280份。
2.根据权利要求1所述的辅助治疗咽喉炎的奶糖,其特征在于由下述重量配比的原料制成:
薄荷6.5份、川贝2.4份,生地3.5份、陈皮0.8份、香菇3.6份,葡萄籽提取物2.5份,白糖260份,葡萄糖浆220份。
3.根据权利要求1或2所述的辅助治疗咽喉炎的奶糖,其特征在于通过下述步骤制备:
(1)将薄荷、川贝、生地、香菇加水煎煮提取清膏,过滤,浓缩至相对密度60℃约1.30;
(2)将陈皮榨汁,过滤;
(3)将1、2步骤所得的浸膏和姜汁,还有葡萄籽提取物混合均匀,备用;
(4)将白糖粉碎至80目;
(5)将白糖粉置于锅内,加适量水,进行熬制,待白糖溶化后加入葡萄糖浆搅拌均匀,再加入步骤3中的混合备用物,搅拌均匀;
(6)出锅注模成型;
(7)出模包装即得。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510672818.2A CN105285288A (zh) | 2015-10-19 | 2015-10-19 | 一种辅助治疗咽喉炎的奶糖及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510672818.2A CN105285288A (zh) | 2015-10-19 | 2015-10-19 | 一种辅助治疗咽喉炎的奶糖及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105285288A true CN105285288A (zh) | 2016-02-03 |
Family
ID=55183800
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510672818.2A Pending CN105285288A (zh) | 2015-10-19 | 2015-10-19 | 一种辅助治疗咽喉炎的奶糖及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105285288A (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105918601A (zh) * | 2016-05-27 | 2016-09-07 | 广西味之坊食品科技有限公司 | 一种预防慢性咽炎的奶糖 |
CN106070989A (zh) * | 2016-06-24 | 2016-11-09 | 安徽小龙人食品股份有限公司 | 一种花粉陈皮胶质型奶糖 |
CN109771493A (zh) * | 2019-03-11 | 2019-05-21 | 重庆化工职业学院 | 一种生津利咽药食同源组合物及应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101057626A (zh) * | 2007-05-31 | 2007-10-24 | 王少林 | 一种川贝薄荷梅及其生产方法 |
CN101791372A (zh) * | 2009-06-29 | 2010-08-04 | 李红 | 一种治疗放射性咽喉炎的中药 |
CN104351450A (zh) * | 2014-10-22 | 2015-02-18 | 张春兰 | 一种橘红润喉奶糖及其制备方法 |
-
2015
- 2015-10-19 CN CN201510672818.2A patent/CN105285288A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101057626A (zh) * | 2007-05-31 | 2007-10-24 | 王少林 | 一种川贝薄荷梅及其生产方法 |
CN101791372A (zh) * | 2009-06-29 | 2010-08-04 | 李红 | 一种治疗放射性咽喉炎的中药 |
CN104351450A (zh) * | 2014-10-22 | 2015-02-18 | 张春兰 | 一种橘红润喉奶糖及其制备方法 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105918601A (zh) * | 2016-05-27 | 2016-09-07 | 广西味之坊食品科技有限公司 | 一种预防慢性咽炎的奶糖 |
CN106070989A (zh) * | 2016-06-24 | 2016-11-09 | 安徽小龙人食品股份有限公司 | 一种花粉陈皮胶质型奶糖 |
CN109771493A (zh) * | 2019-03-11 | 2019-05-21 | 重庆化工职业学院 | 一种生津利咽药食同源组合物及应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Shikov et al. | Medicinal plants of the Russian Pharmacopoeia; their history and applications | |
Khare | Indian herbal remedies: rational western therapy, ayurvedic and other traditional usage, botany | |
KR101445010B1 (ko) | 소염, 부기제거, 진통에 사용되는 중국 생약 조성물, 그 제조 방법 및 용도 | |
KR101090284B1 (ko) | 홍삼과 녹용 추출물을 포함하는 드링크제 및 그의 제조방법 | |
CN104351450A (zh) | 一种橘红润喉奶糖及其制备方法 | |
CN104381557A (zh) | 一种牛大力糖果制作方法 | |
CN102657278A (zh) | 一种芦笋养生茶 | |
CN103168883A (zh) | 可增强免疫力、抗病原微生物、抗病毒的茶饮料颗粒剂及其制备方法 | |
CN105285288A (zh) | 一种辅助治疗咽喉炎的奶糖及其制备方法 | |
CN106362125A (zh) | 一种保健足贴及其使用方法 | |
CN104171226A (zh) | 一种清咽润喉糖果的配方 | |
CN103751568B (zh) | 一种治疗瘙痒症的中药组合物及其制备方法 | |
CN103892475B (zh) | 保健文胸 | |
CN104288736A (zh) | 一种紫菀止咳糖果 | |
CN108813501A (zh) | 具有清热润肺止咳化痰平喘和调节人体机能的养生蜂蜜膏 | |
JP3502072B2 (ja) | 肝臓保護用健康食品組成物(Healthyfoodcompositionforprotectinghepatic) | |
CN110652552A (zh) | 一种伤口愈合配方及制备方法 | |
CN105981853A (zh) | 一种营养功能丰富的温和的暖茶饮料配方 | |
CN103202940A (zh) | 一种消炎药物 | |
CN108057115A (zh) | 一种治疗上呼吸道炎症感染的组合物及其制备方法 | |
CN107712890A (zh) | 一种宁心安神膏滋及其制备方法 | |
CN110063977B (zh) | 一种党参、沙棘复合冲剂及其应用 | |
CN107712845A (zh) | 火棘果提取物在制备提高视觉敏感度保健食品与药品中的用途 | |
CN106720841A (zh) | 一种治疗鼻甲腔肿大的奶糖及其制备方法 | |
CN105125985A (zh) | 一种治疗老年慢性支气管炎的中西药复方制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160203 |
|
WD01 | Invention patent application deemed withdrawn after publication |